Searchable abstracts of presentations at key conferences in endocrinology

ea0022p421 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Thyroid Incidentaloma identified by 18F-Fluorodeoxyglucose Positron Emission Tomography with CT (FDG-PET/CT): clinical relevance

Pagano Loredana , Sama MariaTeresa , Rudoni Marco , Belcastro Sara , Busti Arianna , Caputo Marina , Inglese Eugenio , Aimaretti Gianluca

Thyroid incidentalomas was defined as newly identified thyroid lesions encountered during imaging study for non-thyroid diseases. In the last years, the use of FDG-PET/CT for staging of metastatic diseases was increased. The aim of this retrospective study was to evaluate the FDG-PET/CT uptake, to identify a SUVmax cut off predictive of malignancy and to determine the FDG-PET/CT prognostic role in patients with thyroid incidentalomas. 42 patients (ptx) with incidental thyroid ...

ea0032p473 | Diabetes | ECE2013

Cardiovascular effects of treatment with Liraglutide in a population with type 2 diabetes

Zavattaro Marco , Prodam Flavia , Grazia Mauri Maria , Pagano Loredana , Caputo Marina , Belcastro Sara , Allochis Gabriele , Aimaretti Gianluca

Introduction: Liraglutide, a human GLP-1 analogue, is a new option for the treatment of type 2 diabetes (DM2). The purpose of this study was to evaluate the effects of liraglutide on cardiovascular risk factors in daily clinical practice in a heterogeneous population with DM2.Subjects and methods: Four visits were scheduled in a 1 year study (baseline, 4, 8 and 12 months). Patients with a HbA1c not on target (>7%) during an oral hypoglycemic treatmen...

ea0022p601 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Basal and stimulated GH secretion in Cushing's syndrome: effects of ghrelin and GHRH+arginine

Picu Andreea , Marinazzo Elisa , Prodam Flavia , Broglio Fabio , Belcastro Sara , Aimaretti Gianluca , Giordano Roberta , Ghigo Ezio , Arvat Emanuela

GH secretion is usually impaired in active Cushing’s syndrome (CS), due to concomitant mechanisms, including diminished GHRH and/or increased somatostatin release and impaired pituitary somatotrope responsiveness. Differently, IGF1 levels not parallel GH insufficiency in CS, being reported reduced, normal or increased. Both ghrelin and GHRH+arginine (ARG) are powerful GH secretagogues, influenced by age and/or BMI. In 27 CS (42.7±2.9 years, 28.8±0.9 kg/m2</...

ea0016p434 | Neuroendocrinology | ECE2008

Hypopituitarism and features of the metabolic syndrome in patients with traumatic brain injury (TBI)

Prodam Flavia , Gasco Valentina , Rovere Silvia , Perino Claudio , Golisano Graziella , Busti Arianna , Belcastro Sara , Corneli Ginevra , Aimaretti Gianluca

Objective: Hypopituitarism in adults may be a consequence of TBI, but in the acute or long term management of TBI patients (ptx), endocrine evaluations are not usually included. Aim of this study was to investigate the prevalence of hypopituitarism and metabolic syndrome in a population of 54 severe (n=31) and moderate (n=23) TBI ptx (38 M, 16 F; age (mean±S.D.): 39.8±2.1 years) who had TBI more than 12 months before.<p class="abstext...

ea0037ep293 | Calcium and Vitamin D metabolism | ECE2015

An oral high dose of cholecalciferol restores vitamin D status in deficient postmenopausal HIV-1 infected women independently of protease inhibitors therapy

Pepe Jessica , Mezzaroma Ivano , Fantauzzi Alessandra , Falciano Mario , Salotti Alessandra , Di Traglia Mario , Diacinti Daniele , Belcastro Sara , Piemonte Sara , Cipriani Cristiana , Minisola Salvatore

Introduction: The best repletion and maintenance dosing regimens with cholecalciferol in vitamin D deficient HIV-1 patients remain unknown. Protease inhibitors (PIs) have been shown to inhibit vitamin D 1α- and 25α-hydroxylation in hepatocyte and monocyte cultures. We therefore evaluated the effect of a single high dose of cholecalciferol in vitamin D deficient HIV-1 postmenopausal women undergoing treatment with highly Active Anti-Retroviral Therapy (cART), with and...